Insulet (PODD) Tops Q3 EPS by 12c, provides guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/15/2026
Go back to Insulet (PODD) Tops Q3 EPS by 12c, provides guidance
November 11, 2024 5:53 AM EST
Barclays analyst Matt Miksic raised the price target on Insulet Corporation (NASDAQ: PODD) to $234.00 (from $220.00) while maintaining a Equalweight rating.
The analyst comments "PODD Rallies on Q3 Beat, Fueled by International (+$19MM), Drug Delivery (+$7MM) and Rising Expectations for the T2 Pump Launch: Mgmt delivered a strong beat to vs. our estimates and Bloomberg... More
November 8, 2024 5:13 AM EST
BTIG analyst Marie Thibault raised the price target on Insulet Corporation (NASDAQ: PODD) to $270.00 (from $260.00) while maintaining a Buy rating.
The analyst comments "Insulet reported Q3 revenue of $543.9M (+25.7% y/y), beating consensus estimates of $519.5M and exceeding the ~$510-$524M sales guide. This was driven by a large beat in International Omnipod sales. U.S. Omnipod revenue of $395.6M came in ~$4M higher than expected (cons. $391.9M) while OUS Omnipod revenue of $138M was ~$15M above the Street's forecast (cons. $123.3M). Drug Delivery sales were $10.3M. The full year sales guide... More
